the aid library

LIST OPTIONS

Filter

6972

Sort by:

Direction:

Download (75)

View PDF (332)

Role of APOC in the new strategic direction for Onchocerciasis elimination, co-implementation with Lymphatic filariasis and other health interventions

World Health Organization WHO; African Programme for Onchocerciasis Control APOC (2012) C_WHO

The Onchocerciasis Control Programme in West Africa (OCP) undertook regional and large scale frght against onchocerciasis in West Africa in 1974 using a vector control strategy. By 2002 OCP had succeeded in eliminating the disease as a public health, socio-economic and development problem in 10 out ... more

Download (106)

View PDF (794)

Diagnosis and Clinical Management of Chagas Disease: An Increasing Challenge in Non-Endemic Areas

Suárez, C., Nolder, D., García-Mingo, A. et al. Research and reports in tropical medicine (2022) CC

Chagas disease (CD) is caused by the parasite Trypanosoma cruzi, and it is endemic in Central, South America, Mexico and the South of the United States. It is an important cause of early mortality and morbidity, and it is associated with poverty and stigma. A third of the cases evolve into chronic... more

Download (84)

View PDF (408)

Clinical Spectrum of Schistosomiasis

Carbonell, C.; Rodríguz-Alonso, B.; López-Bernús, A.; et al. MDPI Journal of Clinical Medicine (2021) CC

Schistosomiasis is a helminthic infection and one of the neglected tropical diseases (NTDs). It is caused by blood flukes of the genus Schistosoma. It is an important public health problem, particularly in poverty-stricken areas, especially those within the tropics and subtropics. It is estimated th... more

Download (84)

View PDF (651)

The Chagas disease study landscape: A systematic review of clinical and observational antiparasitic treatment studies to assess the potential for establishing an individual participant-level data plat

Maguire, B.J.; Dahal, P.; Rashan, S. et al. PLOS Neglected Tropical Diseases (2021) CC

Chagas disease (CD), caused by the parasite Trypanosoma cruzi, affects ~6–7 million people worldwide. Significant limitations still exist in our understanding of CD. Harnessing individual participant data (IPD) from studies could support more in-depth analyses to address the many outstanding resea... more

Download (79)

View PDF (513)

Clinical Presentation of T.b. rhodesiense Sleeping Sickness in Second Stage Patients from Tanzania and Uganda

Kuepfer, I.; Hhary, EP.; Mpairwe, A.; Edielu, A.; Burri, C.; Blum, JA. PLOS Neglected Tropical Diseases (2011) CC

A wide spectrum of disease severity has been described for Human African Trypanosomiasis (HAT) due to Trypanosoma brucei rhodesiense (T.b. rhodesiense), ranging from chronic disease patterns in southern countries of East Africa to an increase in virulence towards the north. However, only limited d... more

Download (102)

View PDF (442)

Knowledge, attitudes and practices about human African trypanosomiasis and their implications in designing intervention strategies for Yei county, South Sudan

Bukachi, SA.; Mumbo, AA.; Alak, ACD.; Sebit, W.; Rumunu, J. et al. PLOS Neclected Tropical Diseases (2018) CC

A clear understanding of the knowledge, attitudes and practices (KAP) of a particular community is necessary in order to improve control of human African trypanosomiasis (HAT).New screening and diagnostic tools and strategies were introduced into South Sudan, as part of integrated delivery of primar... more

Download (92)

View PDF (485)

Melarsoprol Resistance in African Trypanosomiasis

Fairlamb, A.H.; Horn, D. Elsevier Ltd. (2018) CC

Arsenical monotherapies were previously very successful for treating human African trypanosomiasis (HAT). Melarsoprol resistance emerged as early as the 1970s and was widespread by the late 1990s. Melarsoprol resistance represents the only example of widespread drug resistance in HAT patients wher... more

Download (89)

View PDF (113)

Target product profile for a test for rhodesiense human African trypanosomiasis diagnosis usable in peripheral health facilities

World Health Organization WHO (2021) C_WHO

The development of this target product profile (TPP) was led by the WHO Department of Control of Ne- glected Tropical Diseases (NTD) following standard WHO guidance for TPP development. In order to identify and prioritize diagnostic needs, a WHO NTD Diagnostics Technical Advisory Group (DTAG) was... more

Download (108)

View PDF (353)

Accelerating towards human African trypanosomiasis elimination: Issues and opportunities

Ozioko ,KU.; Okoye, CI.; Obiezue, RN.; Idika, IK.; Awudu, RA.; Ezewudo, BI.; Ezea, CO. (2019) CC

Human African trypanosomiasis (HAT) has been an alarming global public health issue. The disease affects mainly poor and marginalized people in low-resource settings and is caused by two subspecies of haemoflagellate parasite, Trypanosoma brucei and transmitted by tsetse flies. Progress made in HAT ... more

Download (117)

View PDF (141)

Tsetse Control and Gambian Sleeping Sickness; Implications for Control Strategy

Tirados, I.; Esterhuizen, J.; Kovacic, V.; Mangwiro, TNC.; Vale, GA et al. PLOS Neglected Tropical Diseases (2015) CC

Sleeping sickness is controlled by case detection and treatment but this often only reaches less than 75% of the population. Vector control is capable of completely interrupting HAT transmission but is not used because of expense. We conducted a full scale field trial of a refined vector control tec... more